ReviewFrontiers in immunology2024
Pancreatic islet transplantation: current advances and challenges.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01630850 (Islet Transplantation in Patients With "Brittle" Type I Diabetes), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Islet Transplantation in Patients With "Brittle" Type I Diabetes
Who cites it
44 citing papers in PubMed.
- Review
- Article
- Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Bioengineering Ovarian Endocrine Function: From Follicle Modeling to Cell-Based Hormone Therapy.Advanced healthcare materials · 2026Review
- Experimental models in diabetes research.Laboratory animal research · 2026Review
- Regenerative macrophages enhance stem cell-derived β cell function and engraftment.Science advances · 2026Article
- Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.Biomedical microdevices · 2026Article
- Review
- Discovery and validation of islet regenerative proteins secreted by human multipotent stromal cells.Stem cells translational medicine · 2026Article
- Bioengineering Pancreatic Organoids and iPSC-Derived β-Cells for Diabetes: Materials, Devices, and Translational Challenges.Bioengineering (Basel, Switzerland) · 2026Review
- Apoptotic BMSCs reduce grafted islets apoptosis through the holo-Lcn2/Slc22a17/FeStem cell research & therapy · 2026Article
- Emerging therapies for type 1 diabetes: Immunotherapy and gene editing advances.The Journal of international medical research · 2026Review
- Antigen-specific immunotherapy with a CD4Nature communications · 2026Article
- Modulating immune response for the prevention and treatment of type 1 diabetes.Frontiers in immunology · 2026Review
- Artificial intelligence-driven therapeutics for disease modification in type 1 diabetes: a digital public health and clinical translation framework.Frontiers in public health · 2026Review
- Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat.Diabetes, obesity & metabolism · 2025Article
- A Small-Molecule Mitofusin 1 Agonist Enhances Islet Survival Under Hypoxic Conditions In Vitro and Improves Transplantation Outcomes.Biomolecules · 2025Article
- Drug-Integrating Amphiphilic Nano-Assemblies: 3. PEG-PPS/Palmitate Nanomicelles for Sustained and Localized Delivery of Dexamethasone in Cell and Tissue Transplantations.Pharmaceutics · 2025Article
- Considerations in biodistribution evaluation of iPSC-derived cell therapy: A pancreatic islet cell case study.Molecular therapy. Methods & clinical development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a prevalent chronic disease that traditionally requires severe reliance on medication for treatment. Oral medication and exogenous insulin can only temporarily maintain blood glucose levels and do not cure the disease. Most patients need life-long injections of exogenous insulin. In recent years, advances in islet transplantation have significantly advanced the treatment of diabetes, allowing patients to discontinue exogenous insulin and avoid complications.Long-term follow-up results from recent reports on islet transplantation suggest that they provide significant therapeutic benefit although patients still require immunotherapy, suggesting the importance of future transplantation strategies. Although organ shortage remains the primary obstacle for the development of islet transplantation, new sources of islet cells, such as stem cells and porcine islet cells, have been proposed, and are gradually being incorporated into clinical research. Further research on new transplantation sites, such as the subcutaneous space and mesenteric fat, may eventually replace the traditional portal vein intra-islet cell infusion. Additionally, the immunological rejection reaction in islet transplantation will be resolved through the combined application of immunosuppressant agents, islet encapsulation technology, and the most promising mesenchymal stem cells/regulatory T cell and islet cell combined transplantation cell therapy. This review summarizes the progress achieved in islet transplantation, and discusses the research progress and potential solutions to the challenges faced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.